Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,067,459 papers from all fields of science
Search
Sign In
Create Free Account
Halofenate
Known as:
Benzeneacetic acid, 4-chloro-alpha-(3-(trifluoromethyl)phenoxy)-, 2-(acetylamino)ethyl ester
, Halofenate [Chemical/Ingredient]
A selective peroxisome proliferator-activated receptor gamma (PPAR-gamma) modulator with antilipidemic activity. Halofenate also decreases fasting…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
Broader (2)
Hypolipidemic Agents
Uricosuric Agents
In Blood
agonists
analogs & derivatives
antagonists & inhibitors
Expand
Narrower (1)
MK-185
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1977
1977
Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
L. Krut
,
H. Seftel
,
B. Joffe
South African medical journal = Suid-Afrikaanse…
1977
Corpus ID: 20108839
In a double-blind, randomized study which lasted 48 weeks the effects of clofibrate and halofenate were compared in maturity…
Expand
1977
1977
The Effect of Halofenate – Free Acid on Aggregation – the Release Reaction, Coagulant Activity, and Lipid Metabolism of Human Platelets
H. Akbar
,
N. Ardlie
Thrombosis and Haemostasis
1977
Corpus ID: 23510915
Summary Halofenate – free acid (HFA), the major metabolite of the hypolipidemic drug, halofenate, inhibited platelet aggregation…
Expand
1976
1976
Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat.
R. Cenedella
,
William G. Crouthamel
Journal of Lipid Research
1976
Corpus ID: 11503943
Rats fed a fat-free diet containing no drug, 0.02% or 0.10% halofenate, or 0.25% clofibrate for 14 days were injected…
Expand
1976
1976
The Effect of Halofenate or Halofenate Free Acid on Human, Rat and Guinea Pig Platelet Aggregation
D. H. Minsker
,
P. Jordan
,
P. Kling
,
A. Macmillan
,
H. Hucker
,
D. J. Tocco
Thrombosis and Haemostasis
1976
Corpus ID: 29178083
Summary Halofenate free acid (HFA), the major metabolite of the hypolipemic agent halofenate, blocked the secondary phase of…
Expand
1976
1976
A two‐year crossover therapeutic trial with halofenate and clofibrate
Carlos A. Dujovne
,
Daniel L. Azarnoff
,
Pertti Pentikainen
,
Carl Manion
,
A. Hurwitz
,
Khatab Hassanein
American Journal of the Medical Sciences
1976
Corpus ID: 42013362
Twelve patients with Type IV hyperlipoproteinemia were treated with clofibrate and halofenate in a double blind, crossover trial…
Expand
1976
1976
Changes in serum thyrotropin (TSH) in man during halofenate administration.
P. Davis
,
F. Davis
,
R. Utiger
,
Stanley F. Kulaga
Journal of Clinical Endocrinology and Metabolism
1976
Corpus ID: 8663688
Halofenate, a serum lipid-lowering agent which inhibits binding of thyroid hormone to thyroxine-binding globulin (TBG), was…
Expand
1976
1976
The distribution of halofenate in plasma: a comparative analysis using Scatchard vs. stepwise association constants.
W. Wosilait
,
P. Nagy
Research communications in chemical pathology and…
1976
Corpus ID: 25493310
The distribution of Halofenate between the free and albumin bound forms was calculated by the use of two computer programs using…
Expand
Highly Cited
1975
Highly Cited
1975
Drugs affecting the synthesis of glycerides and phospholipids in rat liver. The effects of clofibrate, halofenate, fenfluramine, amphetamine, cinchocaine, chlorpromazine, demethylimipramine…
D. Brindley
,
M. Bowley
Biochemical Journal
1975
Corpus ID: 8405319
The effects on glycerolipid synthesis of a series of compounds including many drugs were investigated in cell-free preparations…
Expand
1972
1972
Effect of halofenate on binding of various drugs to human plasma proteins and on the plasma half-life of antipyrine in monkeys.
H. Hucker
,
S. Stauffer
,
Samuel E. White
Journal of Pharmacy and Science
1972
Corpus ID: 44406149
Halofenate free acid was shown to reduce markedly the binding of salicylic acid and aspirin in human plasma. Similar, but much…
Expand
1972
1972
Effects of a new hypolipidemic agents, MK-185, on serum thyroxine-binding globulin (TBG) and dialyzable fraction thyroxine.
Paul J. Davis
,
Tah-Hsiung Hsu
,
Joseph R. Bianchine
,
J. P. Morgan
,
Gail Duszczak
Journal of Clinical Endocrinology and Metabolism
1972
Corpus ID: 22213171
MK-185 (halofenate) is a hypo-lipidemic agent which has been shown in short-term clinical trials in hyperlipidemic patients to…
Expand